EGFR/HER2 Kinase Inhibitor TAK-285

Preferred Label : EGFR/HER2 Kinase Inhibitor TAK-285;

NCIt related terms : TAK-285;

NCIt definition : An orally bioavailable, small molecule and dual kinase inhibitor of human epidermal growth factor receptors 1 (EGFR/ErbB1) and 2 (HER2/ErbB2), with potential antineoplastic activity. EGFR/HER2 kinase inhibitor TAK-285 binds to and inhibits EGFR and HER2, which may result in the inhibition of tumor growth and angiogenesis, and tumor regression in EGFR/HER2-expressing tumors. This agent may be active against EGFR/HER2-expressing tumor cells that are resistant to trastuzumab. EGFR and HER2, receptor tyrosine kinases overexpressed in a variety of tumor cell types, play major roles in tumor cell proliferation and tumor vascularization. In addition, TAK-285 appears to pass the blood brain barrier (BBB) and does not appear to be a substrate for efflux pumps.;

UNII : 70CCB438L6;

CAS number : 871026-44-7;

Molecule name : TAK-285;

Details

Origin ID

C90589;

UMLS CUI

C2983788;

Currated CISMeF NLP mapping
- TAK 285 [MeSH concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- TAK 285 [MeSH concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Epidermal Growth Factor Receptor [NCIt concept]
- Receptor Tyrosine-Protein Kinase erbB-2 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients